HUE037724T2 - Eljárás a KCNQ1 gén polimorfizmusán alapuló kezelésre - Google Patents
Eljárás a KCNQ1 gén polimorfizmusán alapuló kezelésreInfo
- Publication number
- HUE037724T2 HUE037724T2 HUE15199673A HUE15199673A HUE037724T2 HU E037724 T2 HUE037724 T2 HU E037724T2 HU E15199673 A HUE15199673 A HU E15199673A HU E15199673 A HUE15199673 A HU E15199673A HU E037724 T2 HUE037724 T2 HU E037724T2
- Authority
- HU
- Hungary
- Prior art keywords
- polymorphisms
- treatment based
- kcnq1 gene
- kcnq1
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16713609P | 2009-04-06 | 2009-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE037724T2 true HUE037724T2 (hu) | 2018-09-28 |
Family
ID=42289491
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15199673A HUE037724T2 (hu) | 2009-04-06 | 2010-04-05 | Eljárás a KCNQ1 gén polimorfizmusán alapuló kezelésre |
| HUE10713287A HUE030667T2 (hu) | 2009-04-06 | 2010-04-05 | Eljárás a KCNQl gén polimorfizmusán alapuló kezelésre |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE10713287A HUE030667T2 (hu) | 2009-04-06 | 2010-04-05 | Eljárás a KCNQl gén polimorfizmusán alapuló kezelésre |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8999638B2 (hu) |
| EP (3) | EP3023506B1 (hu) |
| JP (2) | JP5800798B2 (hu) |
| CA (1) | CA2757713C (hu) |
| ES (3) | ES2673603T3 (hu) |
| HU (2) | HUE037724T2 (hu) |
| SI (2) | SI2417267T1 (hu) |
| WO (1) | WO2010117931A1 (hu) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014022687A8 (pt) | 2012-03-14 | 2021-07-06 | Vanda Pharmaceuticals Inc | uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo |
| CA3024012A1 (en) * | 2016-11-02 | 2018-05-11 | Arog Pharmaceuticals, Inc. | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |
| CA3051829A1 (en) * | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
| JP7250006B2 (ja) | 2017-09-21 | 2023-03-31 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 高投与量バルベナジン製剤ならびにそれに関連する組成物、方法およびキット |
| KR20200066661A (ko) | 2017-10-10 | 2020-06-10 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| CN109371125A (zh) * | 2018-12-31 | 2019-02-22 | 山西医科大学 | 基于kcnq1的心源性猝死相关snp检测试剂盒及检测方法 |
| US11607408B2 (en) | 2019-10-15 | 2023-03-21 | Vanda Pharmaceuticals Inc. | Method of treatment of schizophrenia |
| WO2023201182A1 (en) | 2022-04-13 | 2023-10-19 | Vanda Pharmaceuticals Inc. | Treatment of parkinson's disease and parkinson's disease psychosis |
| NL2033031B1 (en) * | 2022-08-22 | 2024-03-04 | Jiangsu Vocational College Medicine | Single nucleotide polymorphism (snp) molecular marker and kit for assessing tumor progression risk of patient with carcinoma of colon and rectum, and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6345A (en) * | 1849-04-17 | Coefee-eoaster | ||
| US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| AU2927392A (en) | 1991-11-01 | 1993-06-07 | National-Standard Company | Age resistant solder coatings |
| WO2001024681A2 (en) | 1999-08-09 | 2001-04-12 | University Of Utah Research Foundation | Alterations in the long qt syndrome genes kvlqt1 and scn5a and methods for detecting same |
| ATE381626T1 (de) * | 2000-04-13 | 2008-01-15 | Univ Georgetown | Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel |
| WO2003016504A2 (en) | 2001-08-20 | 2003-02-27 | Genaissance Pharmaceuticals, Inc. | Polymorphisms associated with ion-channel disease |
| JP2005504783A (ja) | 2001-08-31 | 2005-02-17 | ノバルティス アクチエンゲゼルシャフト | イロペリドン代謝産物の光学異性体 |
| EP1476575A4 (en) * | 2002-01-18 | 2007-01-10 | Univ Utah Res Found | DETECTION OF INDIVIDUAL NUCLEOTIDE POLYMORPHISMS BY PLANAR WAVEGUIDE |
| AU2003286340A1 (en) | 2002-12-21 | 2004-07-14 | Pfizer Products Inc. | Methods and compositions relating to drug-induced arrhythmia |
| WO2006124646A2 (en) | 2005-05-13 | 2006-11-23 | University Of Chicago | Methods and compostions relating to the pharmacogenetics of different gene variants in the context of irinotecan-based therapies |
| JP5372369B2 (ja) * | 2004-06-22 | 2013-12-18 | ディジマーク コーポレイション | デジタル資産管理、ターゲットを定めたサーチ、及びデジタル透かしを使用するデスクトップサーチ |
| EP1647600A3 (en) | 2004-09-17 | 2006-06-28 | Affymetrix, Inc. (A US Entity) | Methods for identifying biological samples by addition of nucleic acid bar-code tags |
| EP1799865B1 (en) * | 2004-09-30 | 2012-06-06 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| ITMI20051047A1 (it) | 2005-06-07 | 2006-12-08 | Irccs Fond Salvatore Maugeri C | Mutazioni associate alla sindrome del qt lungo e loro uso diagnostico |
| US20110077539A1 (en) | 2009-09-30 | 2011-03-31 | George Alfred L | Methods and Compositions for Prediction of Risk for Sudden Death in Long QT Syndrome |
-
2010
- 2010-04-05 SI SI201031328T patent/SI2417267T1/sl unknown
- 2010-04-05 EP EP15199673.3A patent/EP3023506B1/en active Active
- 2010-04-05 HU HUE15199673A patent/HUE037724T2/hu unknown
- 2010-04-05 JP JP2012504743A patent/JP5800798B2/ja active Active
- 2010-04-05 ES ES15199673.3T patent/ES2673603T3/es active Active
- 2010-04-05 EP EP18160989.2A patent/EP3354753B1/en active Active
- 2010-04-05 CA CA2757713A patent/CA2757713C/en active Active
- 2010-04-05 SI SI201031707T patent/SI3023506T1/en unknown
- 2010-04-05 EP EP10713287.0A patent/EP2417267B1/en active Active
- 2010-04-05 ES ES18160989T patent/ES2792126T3/es active Active
- 2010-04-05 HU HUE10713287A patent/HUE030667T2/hu unknown
- 2010-04-05 US US13/263,074 patent/US8999638B2/en active Active
- 2010-04-05 ES ES10713287.0T patent/ES2604102T3/es active Active
- 2010-04-05 WO PCT/US2010/029921 patent/WO2010117931A1/en active Application Filing
-
2015
- 2015-02-26 US US14/632,914 patent/US9157121B2/en active Active
- 2015-04-30 JP JP2015093382A patent/JP6108633B2/ja active Active
- 2015-09-01 US US14/841,884 patent/US20150368718A1/en not_active Abandoned
-
2017
- 2017-09-14 US US15/705,048 patent/US10563259B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010117931A1 (en) | 2010-10-14 |
| HUE030667T2 (hu) | 2017-05-29 |
| US20150167091A1 (en) | 2015-06-18 |
| JP6108633B2 (ja) | 2017-04-05 |
| EP3354753A1 (en) | 2018-08-01 |
| ES2673603T3 (es) | 2018-06-25 |
| JP2015180639A (ja) | 2015-10-15 |
| JP5800798B2 (ja) | 2015-10-28 |
| EP3023506B1 (en) | 2018-03-14 |
| US20120027871A1 (en) | 2012-02-02 |
| US10563259B2 (en) | 2020-02-18 |
| US9157121B2 (en) | 2015-10-13 |
| SI2417267T1 (sl) | 2017-02-28 |
| SI3023506T1 (en) | 2018-08-31 |
| EP2417267B1 (en) | 2016-08-17 |
| CA2757713A1 (en) | 2010-10-14 |
| EP3023506A1 (en) | 2016-05-25 |
| CA2757713C (en) | 2019-01-29 |
| US20150368718A1 (en) | 2015-12-24 |
| EP2417267A1 (en) | 2012-02-15 |
| ES2792126T3 (es) | 2020-11-10 |
| US20180002756A1 (en) | 2018-01-04 |
| EP3354753B1 (en) | 2020-02-12 |
| ES2604102T3 (es) | 2017-03-03 |
| US8999638B2 (en) | 2015-04-07 |
| JP2012522838A (ja) | 2012-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2417267T1 (sl) | Postopek zdravljenja na podlagi polimorfizmov gena KCNQ1 | |
| HK1208237A1 (en) | Methods for the treatment of gout | |
| IL212348A0 (en) | Treatment method | |
| EP2496684A4 (en) | PHOTOBIOREACTOR SYSTEM AND METHOD OF USE | |
| WO2011005473A9 (en) | Methods for treating or preventing fatigue | |
| EP2352515A4 (en) | METHOD FOR TREATING HEMOPHILIA | |
| EP2350641A4 (en) | Methods of Treatment | |
| IL217492A0 (en) | Treatment method | |
| PT2318573T (pt) | Método de tratamento anticorrosão | |
| PL2413800T3 (pl) | Sposób określania poziomu kondycji fizycznej | |
| EP2418289A4 (en) | METHOD FOR THE DISTINCTION OF GENOTYPES | |
| EP2203432A4 (en) | PROCESSING METHOD | |
| PL385403A1 (pl) | Sposób kształtowania procesów decyzyjnych | |
| GB0914373D0 (en) | Treatment method | |
| GB2452842B (en) | Method of increasing activity | |
| SI2527371T1 (sl) | Metoda za zdravljenje glomerulonefritisa | |
| AU2009903360A0 (en) | Method of Treatment | |
| GB0823435D0 (en) | Method of treatment | |
| AU2008901947A0 (en) | Treatment of Ores | |
| ZA201102198B (en) | Treatment method | |
| GB0904164D0 (en) | Method of treatment | |
| GB0921823D0 (en) | Method of treatment | |
| GB0909807D0 (en) | Method of treatment | |
| AU2009905252A0 (en) | Medical decision support - Improved method | |
| AU2009905269A0 (en) | Method for the treatment of cardiovascular diseases |